Xinhua News Agency, Beijing, November 14
Xinhua News Agency reporter Peng Qian, Ma Xiaocheng, Xu Hongyi
Recently, progress has been made in the research and development of many new crown oral drugs around the world, bringing new hope to the fight against the epidemic
Progress in a variety of oral drugs
Progress in a variety of oral drugs On the 4th of this month, the world's first oral anti-coronavirus drug, Monabivir, jointly developed by Merck and Richbach Biopharmaceuticals of the United States, was first approved by the Medicines and Health Products Administration of the United Kingdom for the treatment of certain patients with COVID-19
Monabilavir is actually an "old drug with new use".
Following the approval of monabiravir, Pfizer announced the latest data on a more effective oral antiviral drug PAXLOVID
AIDS Another "old medicine and new use" oral medicine has also received attention
How to look at advantages and risks
How to look at advantages and risksDing Sheng, director of the Global Health Drug Research and Development Center and dean of the School of Pharmacy of Tsinghua University, told reporters that in terms of large-scale promotion, small-molecule oral drugs have more advantages: convenient for early medication; low synthesis cost, can be stored at room temperature, and easy to purchase and use in developing countries ; It can be quickly used in high-risk groups such as close contacts to help mild patients quickly control their condition
Dean Vikas Sukatmei of Emory University School of Medicine believes that fluvoxamine treatment of new crown is a major victory of "old medicine and new use", which can be used for not being vaccinated or unable to receive monoclonal antibody treatment, and the risk of disease deterioration Higher patients
Several new crown oral drugs have outstanding advantages, but their risks are also worthy of attention
Among them, the mechanism of action of monabiravir is to destroy the RNA replication of the new coronavirus, and scientists are worried that it may affect the human body's DNA (deoxyribonucleic acid) or RNA
Secondly, the new coronavirus may also produce drug-targeted mutations, resulting in drug resistance
Anti-epidemic still needs "combined boxing"
Anti-epidemic still needs "combined boxing" There is a view that there is no need to vaccinate the new crown oral medicine
"Therapeutic drugs and vaccines are not conflicting and antagonistic, but complementary
China Kexue Yuan Guangzhou Institutes of Biomedicine and Health, Distinguished Research Fellow Chen Ling pointed out, vaccines and drugs are complementary "combined" Relationship: Not everyone can be inoculated with the vaccine, the protective effect is not yet clear and persistent; the more part of the innate immunity Poor people are not well vaccinated, and drugs can protect these people.
Special Appointment of the Academy of Sciences The epidemic is far from over, and prevention and control measures, vaccines, and therapeutic drugs are indispensable for the fight against the epidemic in the future
Chen Ling also believes that in the long run, the emergence of oral drugs has indeed injected a "cardiotonic" into the world.
Focus on the new crown pneumonia epidemic
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
